trending Market Intelligence /marketintelligence/en/news-insights/trending/ox5uopk2nu0a2slbfueika2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Acorda Therapeutics chief technology officer to resign


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Acorda Therapeutics chief technology officer to resign

Acorda Therapeutics Inc. said Rick Batycky is leaving as the company's chief technology officer, effective Aug. 20, to be the CEO of a privately held, venture-backed biotechnology company.

David Lawrence, chief of business operations, will take over the position for Acorda's Chelsea, Mass.-based manufacturing facility, which produces Inbrija, a drug indicated to treat symptoms of so-called off periods — times when the effects of a medication wears off — in Parkinson's disease. He will also handle the external manufacturing of Ampyra, a medication to help improve walking in adults with multiple sclerosis.

In addition, Chief Medical Officer Burkhard Blank will lead the company's pharmaceutical development and technical operations team.

Ardsley, N.Y.-based Acorda Therapeutics is a biopharmaceutical company that develops therapies to restore function and improve the lives of people with neurological disorders.